A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: Preliminary results of a proof of concept study

Journal of Vascular and Interventional Radiology

Volumn 25, Issue 2, 2014, Pages 277-287

  Kokabi, Nima ^a   Galt, James R ^a   Xing, Minzhi ^a   Camacho, Juan C ^a   Barron, Bruce J ^a   Schuster, David M ^a   Kim, Hyun S ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MACROSALB TC 99M; YTTRIUM 90;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; BREMS RADIATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; FEMALE; HUMAN; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RADIOACTIVITY; RADIOEMBOLIZATION THERAPY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURVIVAL; TUMOR VOLUME; VERY ELDERLY;

(90)Y; (99M)TC-MAA; BARCELONA CLINIC LIVER CANCER; BCLC; HCC; HEPATOCELLULAR CARCINOMA; LSF; LUNG SHUNT FRACTION; PORTAL VEIN THROMBOSIS; PVT; REGION OF INTEREST; ROI; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; SPECT; TD; TECHNETIUM-99M MACROAGGREGATED ALBUMIN; TUMOR DOSE; YTTRIUM-90;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; EMBOLIZATION, THERAPEUTIC; FEMALE; GLASS; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MICROSPHERES; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PORTAL VEIN; PROSPECTIVE STUDIES; RADIATION DOSAGE; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M AGGREGATED ALBUMIN; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR BURDEN; VENOUS THROMBOSIS; YTTRIUM RADIOISOTOPES;

EID: 84893065354     PISSN: 10510443     EISSN: 15357732     Source Type: Journal    
DOI: 10.1016/j.jvir.2013.11.007     Document Type: Article

References (30)

1. H.B. El-Serag, and A.C. Mason Rising incidence of hepatocellular carcinoma in the United States N Engl J Med 340 1999 745 750
2. M. Kanematsu, R.C. Semelka, P. Leonardou, M. Mastropasqua, and J.K. Lee Hepatocellular carcinoma of diffuse type: MR imaging findings and clinical manifestations J Magn Reson Imaging 18 2003 189 195
3. A. Demirjian, P. Peng, and J.F. Geschwind et al. Infiltrating hepatocellular carcinoma: seeing the tree through the forest J Gastrointest Surg 15 2011 2089 2097
4. E.S. Jang, J.H. Yoon, and J.W. Chung et al. Survival of infiltrative hepatocellular carcinoma patients with preserved hepatic function after treatment with transarterial chemoembolization J Cancer Res Clin Oncol 139 2013 635 643
5. R.R. Lopez Jr, S.H. Pan, and A.L. Hoffman et al. Comparison of transarterial chemoembolization in patients with unresectable, diffuse vs focal hepatocellular carcinoma Arch Surg 137 2002 653 657 discussion 657-658
6. R. Gomez-Rodriguez, M. Romero-Gutierrez, and T. Artaza-Varasa et al. The value of the Barcelona Clinic Liver Cancer and alpha-fetoprotein in the prognosis of hepatocellular carcinoma Rev Esp Enferm Dig 104 2012 298 304
7. J.M. Llovet, S. Ricci, and V. Mazzaferro et al. Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
8. R. Salem, K.G. Thurston, B.I. Carr, J.E. Goin, and J.F. Geschwind Yttrium-90 microspheres: radiation therapy for unresectable liver cancer J Vasc Interv Radiol 13 9 Pt 2 2002 S223 S229
9. P. Hilgard, M. Hamami, and A.E. Fouly et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival Hepatology 52 2010 1741 1749
10. V. Mazzaferro, C. Sposito, and S. Bhoori et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study Hepatology 57 2013 1826 1837
11. B. Sangro, L. Carpanese, and R. Cianni et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona Clinic Liver Cancer stages: a European evaluation Hepatology 54 2011 868 878
12. E. Garin, L. Lenoir, and J. Edeline et al. Boosted selective internal radiation therapy with Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept Eur J Nucl Med Mol Imaging 40 2013 1057 1068
13. N. Kokabi, J. Camacho, and M. Xing et al. World Conference on Interventional Oncology (WCIO) 2013. Poster 5: Safety, efficacy and prognostic factors of survival for yttrium-90 radioembolization therapy in unresectable advanced hepatocellular carcinoma with portal vein thrombosis: a midterm report from a single center prospective feasability study J Vasc Interv Radiol 24 2013 759.e18
14. C. Chiesa, M. Maccauro, and R. Romito et al. Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan Q J Nucl Med Mol Imaging 55 2011 168 197
15. E. Garin, L. Lenoir, and Y. Rolland et al. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results J Nucl Med 53 2012 255 263
16. R. Salem, R.J. Lewandowski, and V.L. Gates et al. Research reporting standards for radioembolization of hepatic malignancies J Vasc Interv Radiol 22 2011 265 278
17. M.J. Berger Distribution of absorbed dose around point sources of electrons and beta particles in water and other media J Nucl Med Suppl 5 1971 5 23
18. W. Snyder, M. Ford, G. Warner, and S. Watson Absorbed dose per unit cumulated activity for selected radionuclides and organs. MIRD Pamphlet Number 11 1975-1976 Society of Nuclear Medicine New York
19. Prajapati HJ, Rafi S, Edalat F, Kooby DA, Kim HS. Safety and efficacy of a circumferential clip-based vascular closure device in cirrhotic and coagulopathic patients with hepatocellular carcinoma after doxorubicin drug-eluting beads transarterial chemoembolization. Cardiovasc Intervent Radiol In press; available online August 10, 2013.
20. M. Ljungberg, and K. Sjogreen-Gleisner The accuracy of absorbed dose estimates in tumours determined by quantitative SPECT: a Monte Carlo study Acta Oncol 50 2011 981 989
21. D. Minarik, M. Ljungberg, P. Segars, and K.S. Gleisner Evaluation of quantitative planar 90Y bremsstrahlung whole-body imaging Phys Med Biol 54 2009 5873 5883
22. D. Minarik, K. Sjogreen Gleisner, and M. Ljungberg Evaluation of quantitative (90)Y SPECT based on experimental phantom studies Phys Med Biol 53 2008 5689 5703
23. U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events, version 4.0. Available at http://evs.nci.nih.gov/ftp1/ CTCAE/CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf. Published June 14, 2010. Accessed October 22, 2013.
24. Y.H. Kao, A.E. Hock Tan, and M.C. Burgmans et al. Image-guided personalized predictive dosimetry by artery-specific SPECT/CT partition modeling for safe and effective 90Y radioembolization J Nucl Med 53 2012 559 566
25. G. Ulrich, O. Dudeck, and C. Furth et al. Predictive value of intratumoral 99mTc-macroaggregated albumin uptake in patients with colorectal liver metastases scheduled for radioembolization with 90Y-microspheres J Nucl Med 54 2013 516 522
26. M. Wondergem, M.L. Smits, and M. Elschot et al. 99mTc-macroaggregated albumin poorly predicts the intrahepatic distribution of 90Y resin microspheres in hepatic radioembolization J Nucl Med 54 2013 1294 1301
27. E. Garin, Y. Rolland, and L. Lenoir et al. Utility of quantitative Tc-MAA SPECT/CT for yttrium-labelled microsphere treatment planning: calculating vascularized hepatic volume and dosimetric approach Int J Mol Imaging 2011 2011 398051
28. R. Lhommel, P. Goffette, and M. Van den Eynde et al. Yttrium-90 TOF PET scan demonstrates high-resolution biodistribution after liver SIRT Eur J Nucl Med Mol Imaging 36 2009 1696
29. S. Walrand, G.D. Flux, and M.W. Konijnenberg et al. Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging? Eur J Nucl Med Mol Imaging 38 Suppl 1 2011 S57 S68
30. M.K. Werner, K. Brechtel, T. Beyer, H. Dittmann, C. Pfannenberg, and J. Kupferschlager PET/CT for the assessment and quantification of (90)Y biodistribution after selective internal radiotherapy (SIRT) of liver metastases Eur J Nucl Med Mol Imaging 37 2010 407 408